IMMUNIC, INC. 8-K

What Happened

• Immunic, Inc. filed an 8-K (filed April 28, 2026) announcing that Michael A. Panzara, M.D., M.P.H., age 59, was appointed Chief Medical Officer effective April 24, 2026. Dr. Panzara joins from Neurvati Neurosciences (CMO, Oct 2022–Mar 2026) and previously held senior medical roles at Wave Life Sciences, Sanofi Genzyme and Biogen, and academic appointments at Harvard Medical School.
• Andreas Muehler, M.D., M.B.A., resigned as CMO effective April 27, 2026, and will transition to a Senior Medical Officer role through the separation date and then serve as a consultant under a Transition, Separation and Consulting Agreement.

Key Details

• Compensation for Dr. Panzara: $600,000 annual base salary; annual bonus target of at least 50% of base; $125,000 signing bonus ($75k first month, $50k after six months); participation in benefits and 30 days paid vacation.
• Equity & vesting for Dr. Panzara: initial inducement option to purchase 300,000 shares (3,000,000 pre 1:10 reverse split) granted April 23, 2026 under the 2026 Inducement Plan; one-half vests after one year, remainder vests monthly over next 24 months; exercise price = closing price on approval date.
• Severance for Dr. Panzara: if terminated without cause or for good reason (outside a change-of-control period) — 12 months base salary, 100% acceleration of unvested equity (exercisable 12 months), COBRA paid 12 months; if during change-of-control period — 18 months base, 100% target bonus, 100% equity acceleration (exercisable 18 months), COBRA 18 months. Severance conditioned on executing a release.
• Transition and severance for Dr. Muehler: employment ended April 27, 2026; will consult up to 10 months at up to 20 hrs/month for $10,000/month; company to pay a lump-sum severance equal to 12 months base salary plus a pro-rated 2026 bonus if earned, and Immunic AG to pay 12 months of fixed annual salary under his service agreement; 100% of outstanding equity awards vest as of separation and vested awards can be exercised for three years.

Why It Matters

• Leadership: A new CMO with extensive industry and clinical development experience could influence the pace and strategy of Immunic’s clinical programs and regulatory interactions — an important consideration for biotech investors tracking development timelines.
• Financial / equity impact: The hire includes cash compensation, a six-figure signing bonus and a 300,000-option inducement grant, which affect near-term cash outflows and potential future equity dilution. Generous severance and full acceleration provisions may create additional contingent liabilities in certain termination or change-of-control scenarios.
• Transition risk mitigation: The separation agreement with Muehler provides consulting continuity and immediate vesting of his equity awards, which can reduce disruption to ongoing programs and minimize potential litigation or retention issues during the handover.